Z-103 Phase III Clinical Study in patients with Taste Disorder - A placebo-controlled superiority study

Phase 3

• Conditions: taste disorders induced by zinc-deficiency

• Registration Number: JPRN-jRCT2080221862
• Lead Sponsor: Zeria Pharmaceutical Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-07-23
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: 260

Inclusion Criteria

Patients diagnosed with the following three types.
1. Zinc-deficient taste disorder
2. Idiopathic taste disorder
3. Drug-induced taste disorder (with some exceptions)

Exclusion Criteria

1. Central nervous system disorder
2. Peripheral neuropathy
3. Intraoral defect and salivary gland disorder
4. Psychiatric disorder
5. Systemic disorders that cause taste disorder

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Final overall efficacy evaluation<br>Filter-paper Disk Method

Secondary Outcome Measures

Name	Time	Method
Efficacy evaluation at each evaluation period<br>Filter-paper Disk Method